inhibitor Lynparza (olaparib) as a first-line treatment of women with breast cancer gene (BRCA) non-mutated advanced epithelial ovarian cancer. Patients on the trial will have just undergone PDS or be ...

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly ...

Patients with platinum-sensitive relapsed ovarian cancer given maintenance olaparib/cediranib had similar progression-free ...

Elahere was found to improve survival in patients with FR-alpha–positive, platinum-resistant, high-grade serous epithelial ...

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

The newly launched “What Science Can Do” campaign, a longstanding tagline for AstraZeneca, centers around the stories of two patients who have benefitted from the company’s therapeutics. Each of their ...

New research identifies specific genetic changes that can increase a person's risk of breast and ovarian cancers, to help guide clinical decision-making.

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person's risk of developing breast and ...

Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated PatientsBoston (September 16, 2024) — Allarity ...